Publisher
Springer Science and Business Media LLC
Reference84 articles.
1. Mohler, J. L. et al. The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 10, 440–448 (2004).
2. Hotte, S. J. & Saad, F. Current management of castrate-resistant prostate cancer. Curr. Oncol. 17 (Suppl. 2), S72–S79 (2010).
3. Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513–1520 (2004).
4. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).
5. Debes, J. D. & Tindall, D. J. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351, 1488–1490 (2004).
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献